A Phase 4 interventional study of Misoprostol (given vaginally) and Letrozole 5 mg in Miscarriage in First Trimester and Missed Miscarriage, sponsored by Nishtar Medical University. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Nishtar Medical University · Phase 4, Interventional, and Treatment
The goal of this clinical trial is to learn whether adding the medicine letrozole to Misoprostol helps women have a complete abortion more often than using Misoprostol alone for the treatment of missed miscarriage (when a pregnancy has stopped developing but has not yet passed naturally).
The main questions this study aims to answer are:
ii. Only those with a single pregnancy are eligible. iii. Women with a previous cesarean section or uterine scar are not included.
What Will Happen in the Study A total of 92 women will take part.
Participants will be randomly assigned to one of two groups:
Group A: Letrozole tablets once daily for 3 days, followed by one dose of vaginal misoprostol.
Group B: Placebo tablets for maximum of 3 days, followed by one dose of vaginal misoprostol.
Doctors will monitor whether the abortion is complete within 24 hours. If it is not, other medical procedures will be offered as needed.
Products of conception will be examined to confirm abortion.
24 studies on the registry are indexed under Abortion, Incomplete; 5 are open to participants now.
This study's planned enrollment of 92 is below the median of 311 across 21 interventional studies indexed under Abortion, Incomplete.
Browse Abortion, Incomplete studies →Nishtar Medical University is the lead sponsor of 29 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vaginal Misoprostol will be instituted after oral placebo
Drug: Misoprostol (given vaginally) · Drug: Placebo
After oral letrozole, vaginal Misoprostol will be instituted
Drug: Misoprostol (given vaginally) · Drug: Letrozole 5 mg
800 micrograms of a single dose of vaginal misoprostol will be given
Also known as: Cytotec, Arthrotec
10 mg oral letrozole for 3 days will be given
Also known as: femara
oral placebo for three days will be given
Complete abortion
The expulsion of both fetus and placenta without operative intervention and no retained products of conception confirmed on ultrasound.
Time frame: From start of study medication after randomization to within 24-hours
Induction-abortion interval
The time interval (in hours) from the administration of first dose of Misoprostol up to the time when the fetus aborted.
Time frame: From start of study medication to abortion, within 24-hours
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Nov 2025, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole
Nishtar Medical University